Medivation, Pfizer Fail Huntington’s Test
Luke Timmerman4/11/11
San Francisco-based Medivation (NASDAQ: MDVN) and its partner, New York-based Pfizer (NYSE: PFE) said today that an experimental drug for Huntington’s disease failed in a pivotal clinical trial. The companies are now discontinuing development of the drug, dimebon, for Huntington’s, although a Phase III clinical trial is continuing for patients with mild-to-moderate Alzheimer’s disease.
